{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T07:17:37Z","timestamp":1768288657636,"version":"3.49.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2007,2,28]],"date-time":"2007-02-28T00:00:00Z","timestamp":1172620800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1007\/s00417-007-0557-x","type":"journal-article","created":{"date-parts":[[2007,2,27]],"date-time":"2007-02-27T14:36:20Z","timestamp":1172586980000},"page":"1273-1280","source":"Crossref","is-referenced-by-count":40,"title":["Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study)"],"prefix":"10.1007","volume":"245","author":[{"given":"Rog\u00e9rio A.","family":"Costa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"Jorge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Calucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Luiz A. S.","family":"Melo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 A.","family":"Cardillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid U.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,2,28]]},"reference":[{"key":"557_CR1","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/archopht.117.9.1161","volume":"117","author":"JW Miller","year":"1999","unstructured":"Miller JW, Schmidt-Erfurth U, Sickenberg M et al (1999) Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol 117:1161\u20131173","journal-title":"Arch Ophthalmol"},{"key":"557_CR2","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/archopht.117.10.1329","volume":"117","author":"Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group","year":"1999","unstructured":"Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials-TAP report no. 1. Arch Ophthalmol 117:1329\u20131345","journal-title":"Arch Ophthalmol"},{"key":"557_CR3","first-page":"198","volume":"119","author":"NM Bressler","year":"2001","unstructured":"Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report no. 2. Arch Ophthalmol 119:198\u2013207","journal-title":"Arch Ophthalmol"},{"key":"557_CR4","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S0161-6420(01)00544-9","volume":"108","author":"Verteporfin in Photodynamic Therapy Study Group","year":"2001","unstructured":"Verteporfin in Photodynamic Therapy Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial-VIP report no. 1. Ophthalmology 108:841\u2013852","journal-title":"Ophthalmology"},{"key":"557_CR5","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/S0161-6420(02)01998-X","volume":"110","author":"KJ Blinder","year":"2003","unstructured":"Blinder KJ, Blumenkranz MS, Bressler NM et al (2003) Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP report no. 3. Ophthalmology 110:667\u2013673","journal-title":"Ophthalmology"},{"key":"557_CR6","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1056\/NEJMoa042760","volume":"351","author":"ES Gragoudas","year":"2004","unstructured":"Gragoudas ES, Adamis AP, Cunningham ET Jr, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group et al (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805\u20132816","journal-title":"N Engl J Med"},{"key":"557_CR7","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1097\/00006982-200510000-00001","volume":"25","author":"VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group","year":"2005","unstructured":"VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group (2005) Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina 25:815\u2013827","journal-title":"Retina"},{"key":"557_CR8","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, MARINA Study Group et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419\u20131431","journal-title":"N Engl J Med"},{"key":"557_CR9","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, ANCHOR Study Group et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432\u20131444","journal-title":"N Engl J Med"},{"key":"557_CR10","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1136\/bjo.2003.027177","volume":"88","author":"E Rechtman","year":"2004","unstructured":"Rechtman E, Danis RP, Pratt LM, Harris A (2004) Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularization in age related macular degeneration. Br J Ophthalmol 88:344\u2013347","journal-title":"Br J Ophthalmol"},{"key":"557_CR11","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/S0161-6420(03)00544-X","volume":"110","author":"RF Spaide","year":"2003","unstructured":"Spaide RF, Sorenson J, Maranan L (2003) Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 110:1517\u20131525","journal-title":"Ophthalmology"},{"key":"557_CR12","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ophtha.2004.08.012","volume":"112","author":"RF Spaide","year":"2005","unstructured":"Spaide RF, Sorenson J, Maranan L (2005) Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 112:301\u2013304","journal-title":"Ophthalmology"},{"key":"557_CR13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/00006982-200601000-00010","volume":"26","author":"M Nicolo","year":"2006","unstructured":"Nicolo M, Ghiglione D, Lai S, Nasciuti F, Cicinelli S, Calabria G (2006) Occult with no classic choroidal neovascularization secondary to age-related macular degeneration treated by intravitreal triamcinolone and photodynamic therapy with verteporfin. Retina 26:58\u201364","journal-title":"Retina"},{"key":"557_CR14","doi-asserted-by":"crossref","unstructured":"Viola F, Morescalchi F, Ratiglia R, Staurenghi G (2006) Ptosis following an intravitreal injection of triamcinolone acetonide. Eye 2006 Feb 24 [Epub ahead of print]","DOI":"10.1038\/sj.eye.6702297"},{"key":"557_CR15","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000090579","volume":"220","author":"T Aggermann","year":"2006","unstructured":"Aggermann T, Stolba U, Brunner S, Binder S (2006) Endophthalmitis with retinal necrosis following intravitreal triamcinolone acetonide injection. Ophthalmologica 220:131\u2013133","journal-title":"Ophthalmologica"},{"key":"557_CR16","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.ajo.2005.10.004","volume":"141","author":"PA Quiram","year":"2006","unstructured":"Quiram PA, Gonzales CR, Schwartz SD (2006) Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 141:580\u2013582","journal-title":"Am J Ophthalmol"},{"key":"557_CR17","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.ajo.2005.06.058","volume":"140","author":"MA Saidel","year":"2005","unstructured":"Saidel MA, Berreen J, Margolis TP (2005) Cytomegalovirus retinitis after intravitreous triamcinolone in an immunocompetent patient. Am J Ophthalmol 140:1141\u20131143","journal-title":"Am J Ophthalmol"},{"key":"557_CR18","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1159\/000088388","volume":"219","author":"CS Yang","year":"2005","unstructured":"Yang CS, Chen MJ, Chou CK, Hsu WM (2005) Refractory severe ocular hypertension after intravitreal triamcinolone acetonide injection. Ophthalmologica 219:413\u2013415","journal-title":"Ophthalmologica"},{"key":"557_CR19","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S0161-6420(02)01743-8","volume":"110","author":"OP Gupta","year":"2003","unstructured":"Gupta OP, Boynton JR, Sabini P, Markowitch W Jr, Quatela V (2003) Proptosis after retrobulbar corticosteroid injections. Ophthalmology 110:443\u2013447","journal-title":"Ophthalmology"},{"key":"557_CR20","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.ophtha.2005.01.033","volume":"112","author":"AJ Dal Canto","year":"2005","unstructured":"Dal Canto AJ, Downs-Kelly E, Perry JD (2005) Ptosis and orbital fat prolapse after posterior sub-Tenon\u2019s capsule triamcinolone injection. Ophthalmology 112:1092\u20131097","journal-title":"Ophthalmology"},{"key":"557_CR21","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0002-9394(02)01426-5","volume":"134","author":"DM Moshfeghi","year":"2002","unstructured":"Moshfeghi DM, Lowder CY, Roth DB, Kaiser PK (2002) Retinal and choroidal vascular occlusion after posterior sub-tenon triamcinolone injection. Am J Ophthalmol 134:132\u2013134","journal-title":"Am J Ophthalmol"},{"key":"557_CR22","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S0002-9394(03)00320-9","volume":"136","author":"S Agrawal","year":"2003","unstructured":"Agrawal S, Agrawal J, Agrawal TP (2003) Conjunctival ulceration following triamcinolone injection. Am J Ophthalmol 136:539\u2013540","journal-title":"Am J Ophthalmol"},{"key":"557_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/00006982-200204000-00002","volume":"22","author":"Eyetech Study Group","year":"2002","unstructured":"Eyetech Study Group (2002) Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 22:143\u2013152","journal-title":"Retina"},{"key":"557_CR24","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/S0161-6420(03)00085-X","volume":"110","author":"Eyetech Study Group","year":"2003","unstructured":"Eyetech Study Group (2003) Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 110:979\u2013986","journal-title":"Ophthalmology"},{"key":"557_CR25","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1167\/iovs.04-0087","volume":"47","author":"IK Kim","year":"2006","unstructured":"Kim IK, Husain D, Michaud N et al (2006) Effect of intravitreal injection of ranibizumab in combination with verteporfin PDT on normal primate retina and choroid. Invest Ophthalmol Vis Sci 47:357\u2013363","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"557_CR26","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1001\/archopht.123.4.509","volume":"123","author":"D Husain","year":"2005","unstructured":"Husain D, Kim I, Gauthier D et al (2005) Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol 123:509\u2013516","journal-title":"Arch Ophthalmol"},{"key":"557_CR27","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1167\/iovs.02-1115","volume":"44","author":"U Schmidt-Erfurth","year":"2003","unstructured":"Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO (2003) Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 44:4473\u20134480","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"557_CR28","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa021491","volume":"349","author":"JC Yang","year":"2003","unstructured":"Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427\u2013434","journal-title":"N Engl J Med"},{"key":"557_CR29","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335\u20132342","journal-title":"N Engl J Med"},{"key":"557_CR30","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/00006982-200603000-00002","volume":"26","author":"J Shahar","year":"2006","unstructured":"Shahar J, Avery RL, Heilweil G et al (2006) Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26:262\u2013269","journal-title":"Retina"},{"key":"557_CR31","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/00006982-200603000-00003","volume":"26","author":"RK Maturi","year":"2006","unstructured":"Maturi RK, Bleau LA, Wilson DL (2006) Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 26:270\u2013274","journal-title":"Retina"},{"key":"557_CR32","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/00006982-200603000-00001","volume":"26","author":"RP Manzano","year":"2006","unstructured":"Manzano RP, Peyman GA, Khan P, Kivilcim M (2006) Testing intravitreal toxicity of bevacizumab (Avastin). Retina 26:257\u2013261","journal-title":"Retina"},{"key":"557_CR33","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3928\/1542-8877-20050701-14","volume":"36","author":"PJ Rosenfeld","year":"2005","unstructured":"Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36:331\u2013335","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"557_CR34","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3928\/1542-8877-20050701-15","volume":"36","author":"PJ Rosenfeld","year":"2005","unstructured":"Rosenfeld PJ, Fung AE, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 36:336\u2013339","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"557_CR35","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","volume":"113","author":"RL Avery","year":"2006","unstructured":"Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363\u2013372","journal-title":"Ophthalmology"},{"key":"557_CR36","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/00006982-200604000-00001","volume":"26","author":"RF Spaide","year":"2006","unstructured":"Spaide RF, Laud K, Fine HF et al (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26:383\u2013390","journal-title":"Retina"},{"key":"557_CR37","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1167\/iovs.06-0433","volume":"47","author":"RA Costa","year":"2006","unstructured":"Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA, Scott IU (2006) Intravitreal bevacizumab (Avastin) for choroidal neovascularization caused by age-related macular degeneration (IBeNA Study): results of a dose-escalation study. Invest Ophthalmol Vis Sci 47:4569\u20134578","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"557_CR38","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/00006982-200603000-00005","volume":"26","author":"D Iturralde","year":"2006","unstructured":"Iturralde D, Spaide RF, Meyerle CB et al (2006) Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 26:279\u2013284","journal-title":"Retina"},{"key":"557_CR39","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1111\/j.1600-0420.2006.00731.x","volume":"84","author":"JS Paula","year":"2006","unstructured":"Paula JS, Jorge R, Costa RA, Rodrigues MLV, Scott IU (2006) Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma. Acta Ophthalmol Scand 84:556\u2013557","journal-title":"Acta Ophthalmol Scand"},{"key":"557_CR40","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/00006982-200603000-00004","volume":"26","author":"RF Spaide","year":"2006","unstructured":"Spaide RF, Fisher YL (2006) Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26:275\u2013278","journal-title":"Retina"},{"key":"557_CR41","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1097\/01.iae.0000246884.76018.63","volume":"26","author":"R Jorge","year":"2006","unstructured":"Jorge R, Costa RA, Calucci D, Cintra L, Scott IU (2006) Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBePe Study). Retina 26:1006\u20131013","journal-title":"Retina"},{"key":"557_CR42","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0039-6257(05)80092-X","volume":"39","author":"AC Bird","year":"1995","unstructured":"Bird AC, Bressler NM, Bressler SB et al (1995) An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 39:367\u2013374","journal-title":"Surv Ophthalmol"},{"key":"557_CR43","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S0161-6420(01)00544-9","volume":"108","author":"Verteporfin in Photodynamic Therapy Study Group","year":"2001","unstructured":"Verteporfin in Photodynamic Therapy Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial. VIP report no 1. Ophthalmology 108:841\u2013852","journal-title":"Ophthalmology"},{"key":"557_CR44","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1751-1097.1992.tb04222.x","volume":"55","author":"BW Henderson","year":"1992","unstructured":"Henderson BW, Dougherty TJ (1992) How does photodynamic therapy work? Photochem Photobiol 55:145\u2013157","journal-title":"Photochem Photobiol"},{"key":"557_CR45","unstructured":"Grossweiner LI (1994) The science of phototherapy. CRC Press, Boca Raton, FL, USA, pp 27\u201349, 139\u2013155, 175\u2013177"},{"key":"557_CR46","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/00006982-200304000-00004","volume":"23","author":"RA Costa","year":"2003","unstructured":"Costa RA, Farah ME, Cardillo JA, Calucci DS, Williams GA (2003) Immediate indocyanine green angiography and optical coherence tomography evaluation after photodynamic therapy of subfoveal choroidal neovascularization. Retina 23:159\u2013165","journal-title":"Retina"},{"key":"557_CR47","first-page":"835","volume":"120","author":"U Schmidt-Erfurth","year":"2002","unstructured":"Schmidt-Erfurth U, Laqua H, Schloetzer-Schrehard U et al (2002) Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol 120:835\u2013843","journal-title":"Arch Ophthalmol"},{"key":"557_CR48","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1136\/bjo.2003.018754","volume":"88","author":"F Gelisken","year":"2004","unstructured":"Gelisken F, Lafaut BA, Inhoffen W et al (2004) Clinicopathological findings of choroidal neovascularisation following verteporfin photodynamic therapy. Br J Ophthalmol 88:207\u2013211","journal-title":"Br J Ophthalmol"},{"key":"557_CR49","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1136\/bjo.85.9.1086","volume":"85","author":"UEK Schnurrbusch","year":"2001","unstructured":"Schnurrbusch UEK, Welt K, Horn LC et al (2001) Histological findings of surgically excised choroidal neovascular membranes after photodynamic therapy. Br J Ophthalmol 85:1086\u20131091","journal-title":"Br J Ophthalmol"},{"key":"557_CR50","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1097\/00006982-200110000-00010","volume":"21","author":"NG Ghazi","year":"2001","unstructured":"Ghazi NG, Jabbour NM, De la Cruz ZC et al (2001) Clinicopathologic studies of age-related macular degeneration with classic subfoveal choroidal neovascularization treated with photodynamic therapy. Retina 21:478\u2013486","journal-title":"Retina"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-007-0557-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-007-0557-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-007-0557-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-007-0557-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T18:12:44Z","timestamp":1581963164000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-007-0557-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,28]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["557"],"URL":"https:\/\/doi.org\/10.1007\/s00417-007-0557-x","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,28]]}}}